An Open-label, Multicenter, Phase II Study of Dovitinib in Advanced Thyroid Cancer
NCT01964144
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
40
Enrollment
OTHER
Sponsor class
Conditions
Thyroid Cancer
Interventions
DRUG:
Dovitinib
Sponsor
Yonsei University